Long-Term Follow-Up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Cancer - United States
doi 10.1002/cncr.32504
Full Text
Open PDFAbstract
Available in full text
Date
September 25, 2019
Authors
Publisher
Wiley